What factors affect a sufficient dose of carbopplatin?

Member of a class of medicines known as alkylating substances, carbopplatin is a drug used mainly as treatment of cancer, especially for ovarian cancer. Alkylating agents work by disrupting the growth of cancer cells, which eventually causes these cells to die at greater speed than in healthy cells in the patient's body. Some medicines can interact with carbopplatin, so it is necessary to adjust their doses if they cannot be completely removed from the patient's treatment regimen. Other factors that may affect the appropriate dose of carbopplatin include the level of kidney function, response to previous treatment and form of cancer to be treated.

As a monotherapy of ovarian cancer is a standard dose for adult carbopplatins 360 mg/m2 carbopplatin, which is administered intravenously on the day once every four weeks. Repeated doses are not generally administered until the number of patient plates is no more than 100,000 and its number of neutrophils is more than 2,000. When bacarbopplatin is administered along cyclophosphamideKa is reduced to 300 mg/m2 for six cycles of four weeks. Instead, some doctors apply an algorithm known as Calvert formula to determine the doses of carbopplatin.

In determining the appropriate dose of carbopplatin for the administration of patients who were treated in the past carbopplatin, it is essential that their number of plates and the condition of the procedure be measured before treatment. In patients with a number of platelets of more than 100,000 and neutrophils greater than 2,000, the carbopplatin dose may be increased by 125 percent, while patients with a number of inserts less than 50,000 or neutrophils should receive 75 percent of standard dose. Patients with a number of inserts between 50,000 and 100,000 and the number of neutrophils of 500 to 2,000 do not require any carboplatin dose. Thadice showing severe myelosuppression in some cases received doses of up to 50 to 60 percent of a typical dose. These modifications of carbopplatins do the same whenis used as a monthly agent or when used in combination with cyclophosphamide.

Further adjustments to carbopplatin dosage may be required in patients suffering from reduced kidney function, as renal function can cause idiosyncratic increase in drug serum levels. These patients are exposed to significantly higher risk of developing severe leukopenia, thrombocytopenia and neutropenia than other patients, even with the following modifications of their carboplatin dose. Patients with Clearence levels of 41 to 59 ml/min should have 250 mg/m2 on the day of treatment. Those with creatinine clearance 16 to 40 ml/min should receive 200 mg/m2 on the first day. These dosage recommendations must be adjusted according to the patient tolerance and the level of suppression of the bone marrow during subsequent treatments.